Cao H, Mani I, Vincent R, Mugerwa R, Mugyenyi P, Kanki P, Ellner J, Walker B D
Massachusetts General Hospital-East, AIDS Research Center, Charlestown, MA 02129, USA.
J Infect Dis. 2000 Nov;182(5):1350-6. doi: 10.1086/315868. Epub 2000 Oct 9.
The first prophylactic human immunodeficiency virus type 1 (HIV-1) vaccine trial in Africa, with a clade B immunogen, is currently under way in Uganda, in a region where clades A and D are endemic. The use of a B clade vaccine is based on anticipated cross-recognition of endemic strains of HIV-1 in Uganda, but, in fact, little is known about the cytotoxic T lymphocyte (CTL) responses in that region. Seventeen HIV-1-infected volunteers from Kampala, Uganda, were studied to determine the immune responses elicited by natural infection with local HIV-1 strains. Despite the presence of broad cross-clade recognition, the CTL responses to the infecting viral clade were highest in most people. Recognition of nonendemic clade B antigens was similar to that of the coendemic local clade, and, in some instances, cross-recognition of clade B was greater. Nevertheless, the degree of cross-clade cellular responses we observed lends justification to the use of clade B-based immunogens in the current phase 1 vaccine trial in Uganda.
在乌干达一个A亚型和D亚型流行的地区，目前正在开展非洲首个使用B亚型免疫原的预防性1型人类免疫缺陷病毒（HIV-1）疫苗试验。使用B亚型疫苗是基于预期乌干达HIV-1流行毒株会产生交叉识别，但实际上，对该地区细胞毒性T淋巴细胞（CTL）反应了解甚少。对来自乌干达坎帕拉的17名HIV-1感染志愿者进行了研究，以确定当地HIV-1毒株自然感染引发的免疫反应。尽管存在广泛的跨亚型识别，但在大多数人中，对感染病毒亚型的CTL反应最高。对非流行B亚型抗原的识别与共同流行的当地亚型相似，在某些情况下，对B亚型的交叉识别更强。然而，我们观察到的跨亚型细胞反应程度为在乌干达当前的1期疫苗试验中使用基于B亚型的免疫原提供了依据。
